PostEra
PostEra is building a modern 21st century biopharma. We're using our advances in machine learning to accelerate Medicinal Chemistry and bring more cures to patients. PostEra advances small molecule programs through partnerships with biopharma while also advancing its own internal pipeline. We've raised $26M from top investors and closed $1Bn in AI partnerships, signing multi-year agreements with Amgen, Pfizer and the NIH. PostEra also launched and led the world's largest open-science drug discov
Y Combinator
yc-company-directory #4257PostEra is building a modern 21st century biopharma. We're using our advances in machine learning to accelerate Medicinal Chemistry and bring more cures to patients. PostEra advances small molecule programs through partnerships with biopharma while also advancing its own internal pipeline. We've raised $26M from top investors and closed $1Bn in AI partnerships, signing multi-year agreements with Amgen, Pfizer and the NIH. PostEra also launched and led the world's largest open-science drug discov
sourcePostEra is classified as AI infrastructure from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to PostEra
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
b12 Labs
match 67b12 makes high-value molecules that are otherwise hard to make. We help pharma companies plan and make new drugs, accelerating early-stage drug discovery from years to months. Andres built the first AI agent that can autonomously think and make molecules in a robotic lab, published in Nature Machine Intelligence (1000+ citations), and won the best paper award at the NeurIPS AI for Science conference. Zlatko is a 3x National Chemistry Olympiad champion, competed at IChO level, and medicinal chemi
shared extracted concept terms: machine; shared product terms: molecule, drug, year, machine; shared affiliation: Y Combinator
Enjamb Labs
match 56Enjamb runs the entire drug program for biopharma teams, from discovery to FDA approval. Pharma runs on decades of closed legacy systems like Benchling, Veeva, Medidata, and SAS, with no AI layer and no MCP to connect agents to them. So we built that connection layer in one platform. Our agents run on top of their existing systems and data, with no migration, and do the work across the whole program: clinical evidence, trial design, statistical programming, and regulatory submissions. In just 3
shared extracted concept terms: biopharma; shared product terms: drug, program, biopharma, clos; shared product theme: health and clinical care; shared affiliation: Y Combinator
MDalgorithms Inc.
match 51MDalgorithms is revolutionizing dermatology by delivering convenient, effective AI-powered solutions for skin and hair care. Since pioneering machine-learning models for acne treatment in 2017, we’ve advanced to develop the world’s first AI-powered scalp analysis for hair regrowth. Our proprietary AI technology, built entirely in-house, analyzes blemishes, lesions, and hair conditions with unmatched precision, utilizing the largest global dataset of acne and scalp images. Clinically validated an
shared extracted concept terms: machine; shared product terms: machine, ve, advanc, largest; shared product theme: health and clinical care; same category: AI infrastructure; shared affiliation: Y Combinator
Embleema
match 49We accelerate new drug releases to patients by providing faster, regulatory-grade real-world data to life sciences and regulators.
shared extracted concepts: patients; shared product terms: accelerate, drug, patient, science; shared product theme: health and clinical care
Perlara
match 46Perlara 1.0 (Feb 2014 - Feb 2019) launched early R&D joint ventures called PerlQuests with highly motivated rare disease families, companies or impact investors. We screened gene-edited patient avatars for repurposable drugs in order to build a predictive R&D engine called ArkBase. We planned to monetize programs based on ArkBase predictions by selectively spinning out asset-centric clinical development NewCos. Perlara 1.5 (March 2019 - April 2020) was the transition to a one-person virtual clin
shared product terms: launch, investor, patient, drug; shared product theme: health and clinical care; shared affiliation: Y Combinator
Osmind
match 46Osmind is the premier platform for clinicians and researchers advancing new life-saving mental health treatments. Today, mental health disorders are one of the leading causes of death worldwide, especially among young adults, and are tied to shortening lifespans. While there have been developments in new psychiatric medications since the first FDA approval in 1954, today there is a growing movement among clinicians, patients, and researchers who are recognizing the need to accelerate new science
shared product terms: advanc, while, patient, accelerate; shared product theme: health and clinical care; shared affiliation: Y Combinator